Melissa M Herbst-Kralovetz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6482343/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multi-omics data integration reveals metabolome as the top predictor of the cervicovaginal microenvironment. PLoS Computational Biology, 2022, 18, e1009876.	3.2	21
2	Cervicovaginal DNA Virome Alterations Are Associated with Genital Inflammation and Microbiota Composition. MSystems, 2022, 7, e0006422.	3.8	14
3	Connecting microbiome and menopause for healthy ageing. Nature Microbiology, 2022, 7, 354-358.	13.3	11
4	Clinical and Personal Lubricants Impact the Growth of Vaginal Lactobacillus Species and Colonization of Vaginal Epithelial Cells: An in Vitro Study. Sexually Transmitted Diseases, 2021, 48, 63-70.	1.7	11
5	The role of gut and genital microbiota and the estrobolome in endometriosis, infertility and chronic pelvic pain. Human Reproduction Update, 2021, 28, 92-131.	10.8	78
6	Veillonellaceae family members uniquely alter the cervical metabolic microenvironment in a human three-dimensional epithelial model. Npj Biofilms and Microbiomes, 2021, 7, 57.	6.4	25
7	Designing Inclusive HPV Cancer Vaccines and Increasing Uptake among Native Americans—A Cultural Perspective Review. Current Oncology, 2021, 28, 3705-3716.	2.2	10
8	Bacterial vaginosis and health-associated bacteria modulate the immunometabolic landscape in 3D model of human cervix. Npj Biofilms and Microbiomes, 2021, 7, 88.	6.4	42
9	Immunometabolic Analysis of Mobiluncus mulieris and Eggerthella sp. Reveals Novel Insights Into Their Pathogenic Contributions to the Hallmarks of Bacterial Vaginosis. Frontiers in Cellular and Infection Microbiology, 2021, 11, 759697.	3.9	6
10	Interleukin-36Î ³ Is Elevated in Cervicovaginal Epithelial Cells in Women With Bacterial Vaginosis and In Vitro After Infection With Microbes Associated With Bacterial Vaginosis. Journal of Infectious Diseases, 2020, 221, 983-988.	4.0	24
11	Host–vaginal microbiota interactions in the pathogenesis of bacterial vaginosis. Current Opinion in Infectious Diseases, 2020, 33, 59-65.	3.1	97
12	Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment. Npj Precision Oncology, 2020, 4, 22.	5.4	18
13	Members of <i>Prevotella</i> Genus Distinctively Modulate Innate Immune and Barrier Functions in a Human Three-Dimensional Endometrial Epithelial Cell Model. Journal of Infectious Diseases, 2020, 222, 2082-2092.	4.0	21
14	The microbiome and gynaecological cancer development, prevention and therapy. Nature Reviews Urology, 2020, 17, 232-250.	3.8	194
15	3D Oral and Cervical Tissue Models for Studying Papillomavirus Hostâ€Pathogen Interactions. Current Protocols in Microbiology, 2020, 59, e129.	6.5	16
16	Abstract A094: Integrative multi-omics approach reveals complex interplay between HPV, host and microbiome during cervical carcinogenesis in Hispanic and non-Hispanic women. , 2020, , .		0
17	Personal and Clinical Vaginal Lubricants: Impact on Local Vaginal Microenvironment and Implications for Epithelial Cell Host Response and Barrier Function. Journal of Infectious Diseases, 2019, 220, 2009-2018.	4.0	29
18	IL-36γ Is a Key Regulator of Neutrophil Infiltration in the Vaginal Microenvironment and Limits Neuroinvasion in Genital HSV-2 Infection. Journal of Immunology, 2019, 203, 2655-2664.	0.8	11

#	Article	IF	CITATIONS
19	Analysis of Host Responses to Neisseria gonorrhoeae Using a Human Three-Dimensional Endometrial Epithelial Cell Model. Methods in Molecular Biology, 2019, 1997, 347-361.	0.9	5
20	Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis. Scientific Reports, 2019, 9, 7333.	3.3	70
21	Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling. EBioMedicine, 2019, 44, 675-690.	6.1	142
22	Chronic immune barrier dysregulation among women with a history of violence victimization. JCI Insight, 2019, 4, .	5.0	4
23	Microbiota–drug interactions: Impact on metabolism and efficacy of therapeutics. Maturitas, 2018, 112, 53-63.	2.4	71
24	Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women. Scientific Reports, 2018, 8, 7593.	3.3	155
25	Uterine Microbiota: Residents, Tourists, or Invaders?. Frontiers in Immunology, 2018, 9, 208.	4.8	227
26	IL-36Î ³ induces a transient HSV-2 resistant environment that protects against genital disease and pathogenesis. Cytokine, 2018, 111, 63-71.	3.2	19
27	Human Three-Dimensional Endometrial Epithelial Cell Model To Study Host Interactions with Vaginal Bacteria and Neisseria gonorrhoeae. Infection and Immunity, 2017, 85, .	2.2	72
28	Estrogen–gut microbiome axis: Physiological and clinical implications. Maturitas, 2017, 103, 45-53.	2.4	485
29	Three-Dimensional Rotating Wall Vessel-Derived Cell Culture Models for Studying Virus-Host Interactions. Viruses, 2016, 8, 304.	3.3	36
30	IL-36Î ³ Augments Host Defense and Immune Responses in Human Female Reproductive Tract Epithelial Cells. Frontiers in Microbiology, 2016, 7, 955.	3.5	32
31	New Systems for Studying Intercellular Interactions in Bacterial Vaginosis. Journal of Infectious Diseases, 2016, 214, S6-S13.	4.0	41
32	Menopause and the vaginal microbiome. Maturitas, 2016, 91, 42-50.	2.4	224
33	Antimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implications. Human Reproduction Update, 2015, 21, 353-377.	10.8	159
34	The vaginal and gastrointestinal microbiomes in gynecologic cancers: A review of applications in etiology, symptoms and treatment. Gynecologic Oncology, 2015, 138, 190-200.	1.4	108
35	Norovirus Narita 104 Virus-Like Particles Expressed in <i>Nicotiana benthamiana</i> Induce Serum and Mucosal Immune Responses. BioMed Research International, 2014, 2014, 1-9.	1.9	26
36	TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines. Human Vaccines and Immunotherapeutics, 2014, 10, 410-416.	3.3	27

#	Article	IF	CITATIONS
37	Bacteria in the Vaginal Microbiome Alter the Innate Immune Response and Barrier Properties of the Human Vaginal Epithelia in a Species-Specific Manner. Journal of Infectious Diseases, 2014, 209, 1989-1999.	4.0	240
38	Overcoming barriers in the mucosal delivery of virus-like particle-based vaccines. Therapeutic Delivery, 2014, 5, 741-744.	2.2	3
39	Lack of Norovirus Replication and Histo-Blood Group Antigen Expression in 3-Dimensional Intestinal Epithelial Cells. Emerging Infectious Diseases, 2013, 19, 431-438.	4.3	69
40	Microbial Products Alter the Expression of Membrane-Associated Mucin and Antimicrobial Peptides in a Three-Dimensional Human Endocervical Epithelial Cell Model1. Biology of Reproduction, 2012, 87, 132.	2.7	67
41	Culturing and Applications of Rotating Wall Vessel Bioreactor Derived 3D Epithelial Cell Models. Journal of Visualized Experiments, 2012, , .	0.3	51
42	Intranasal Vaccination with Murabutide Enhances Humoral and Mucosal Immune Responses to a Virus-Like Particle Vaccine. PLoS ONE, 2012, 7, e41529.	2.5	41
43	A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. Proceedings of the United States of America, 2011, 108, 20695-20700.	7.1	73
44	Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine, 2011, 29, 5221-5231.	3.8	83
45	Organotypic 3D cell culture models: using the rotating wall vessel to study host–pathogen interactions. Nature Reviews Microbiology, 2010, 8, 791-801.	28.6	257
46	Development and Characterization of a Three-Dimensional Organotypic Human Vaginal Epithelial Cell Model1. Biology of Reproduction, 2010, 82, 617-627.	2.7	87
47	An Intranasally Delivered Toll-Like Receptor 7 Agonist Elicits Robust Systemic and Mucosal Responses to Norwalk Virus-Like Particles. Vaccine Journal, 2010, 17, 1850-1858.	3.1	45
48	ORIGINAL ARTICLE: Quantification and Comparison of Tollâ€Like Receptor Expression and Responsiveness in Primary and Immortalized Human Female Lower Genital Tract Epithelia. American Journal of Reproductive Immunology, 2008, 59, 212-224.	1.2	123
49	Quantification of Poly(I:C)-Mediated Protection against Genital Herpes Simplex Virus Type 2 Infection. Journal of Virology, 2006, 80, 9988-9997.	3.4	67